EligibleTrials

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

Recruiting · NCT06285643 · Interventional (participants receive a specific treatment) · Lead sponsor: AskBio Inc

View the official record on ClinicalTrials.gov →
Parkinson's disease

Interventions studied

AAV2-GDNF gene therapycontrol surgery

What this trial is about

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

Who can take part

Age range
45 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

46 locations listed across 20 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.